LOGGI, ELISABETTA
 Distribuzione geografica
Continente #
NA - Nord America 3.532
AS - Asia 2.837
EU - Europa 2.066
AF - Africa 182
SA - Sud America 147
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 8.766
Nazione #
US - Stati Uniti d'America 3.496
SG - Singapore 838
CN - Cina 707
VN - Vietnam 679
GB - Regno Unito 529
SE - Svezia 351
DE - Germania 266
IT - Italia 243
HK - Hong Kong 205
FR - Francia 138
IN - India 131
BR - Brasile 104
UA - Ucraina 102
IE - Irlanda 88
RU - Federazione Russa 87
NL - Olanda 60
KR - Corea 54
ZA - Sudafrica 53
TG - Togo 51
JP - Giappone 45
BE - Belgio 40
FI - Finlandia 36
EE - Estonia 34
JO - Giordania 32
CI - Costa d'Avorio 31
PH - Filippine 23
CH - Svizzera 22
SC - Seychelles 21
CA - Canada 20
TH - Thailandia 19
AR - Argentina 18
BD - Bangladesh 17
GR - Grecia 15
BG - Bulgaria 14
TW - Taiwan 14
IR - Iran 13
IQ - Iraq 11
MX - Messico 11
EC - Ecuador 8
PL - Polonia 8
AT - Austria 7
ID - Indonesia 7
TR - Turchia 7
ES - Italia 6
LB - Libano 6
NG - Nigeria 6
PK - Pakistan 6
SA - Arabia Saudita 6
CL - Cile 4
RO - Romania 4
VE - Venezuela 4
CO - Colombia 3
DK - Danimarca 3
ET - Etiopia 3
MY - Malesia 3
PE - Perù 3
PT - Portogallo 3
RS - Serbia 3
TN - Tunisia 3
CR - Costa Rica 2
DZ - Algeria 2
PY - Paraguay 2
QA - Qatar 2
SN - Senegal 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BJ - Benin 1
CG - Congo 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GN - Guinea 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LY - Libia 1
MA - Marocco 1
ML - Mali 1
MT - Malta 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
UY - Uruguay 1
YT - Mayotte 1
Totale 8.766
Città #
Singapore 611
Southend 459
Fairfield 366
Ashburn 349
Chandler 341
Hong Kong 195
San Jose 194
Woodbridge 180
Ann Arbor 175
Dong Ket 158
Houston 155
Seattle 150
Santa Clara 149
Wilmington 148
Ho Chi Minh City 143
Cambridge 134
Hefei 134
Hanoi 115
Princeton 111
Dublin 88
Beijing 85
Boardman 72
Jacksonville 63
Lauterbourg 51
Lomé 51
Nanjing 51
Dallas 49
Seoul 47
Westminster 47
Padova 44
Brussels 39
Tokyo 37
Los Angeles 35
Amman 32
Bologna 32
Jinan 32
Abidjan 31
Buffalo 27
Berlin 26
Changsha 25
Council Bluffs 24
Da Nang 24
San Diego 24
Helsinki 23
Shenyang 23
Frankfurt am Main 22
Haiphong 22
Turin 22
Milan 20
São Paulo 20
Munich 19
Redondo Beach 18
Hebei 17
Nanchang 17
Bern 15
Bremen 15
Saint Petersburg 15
Bengaluru 14
New York 14
Rome 14
Bangkok 13
Mülheim 13
Sofia 13
Zhengzhou 13
Guangzhou 11
Johannesburg 11
Mahé 11
Tianjin 11
Amsterdam 10
Des Moines 10
Florence 10
San Francisco 10
Toronto 10
Turku 10
Hải Dương 9
London 9
Ningbo 9
Redmond 9
Dearborn 8
Kunming 8
Taizhou 8
Xi'an 8
Yubileyny 8
Biên Hòa 7
Dolo 7
Falkenstein 7
Orem 7
Phoenix 7
Shanghai 7
Washington 7
Abeokuta 6
Bình Phước 6
Haikou 6
Jiaxing 6
Lanzhou 6
Medford 6
Paris 6
Quezon City 6
Redwood City 6
Vienna 6
Totale 5.954
Nome #
Adaptive response in Hepatitis B virus infection 250
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 236
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. 226
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 203
Low replication and variability of HBV pre-core in concomitant infection with hepatitis B and hepatitis C viruses 202
Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice 199
Vitamins in the treatment of chronic viral hepatitis. 198
Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients 194
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma 193
Virological analysis, genotypes and mutational patterns of the HBV pre-core/core gene in HBV/HCV-related hepatocellular carcinoma. 193
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 192
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. 189
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 188
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients. 187
Chronic hepatitis B: Are we close to a cure? 181
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 180
Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: A systematic review and meta-analysis 179
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B. 178
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 176
The increase of Ribavirin dose improves sustained virological response in HCV-Genotype 1 patients with a partial response to PEG-Interferon and Ribavirin. 173
Hepatitis B virus and immune response. 172
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B 171
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C. 169
Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report 168
Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. 168
Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis 167
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 167
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 167
Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot" 163
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. 163
Immunological modifications during treatment with thymosin alpha 1 plus antiviral therapy in chronic hepatitis C. 162
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 156
Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. 153
Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature 152
Effect of liver transplantation on tuftsin activity and phagocytic activity of neutrophyl granulocytes in patients with liver cirrhosis. 151
Ketoprofen, peginterferon-alpha2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. 146
Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment 146
Development of psychiatric symptoms during antiviral therapy for chronic hepatitis C: a retrospective study on 590 subjects. 146
Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. 144
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 142
SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses 142
Uno studio retrospettivo su 590 soggetti: sintomi psichiatrici durante la terapia antivirale per l’epatite cronica C. 139
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 136
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 132
Virological Treatment Monitoring for Chronic Hepatitis B 126
Proteomics of immune cells from liver tumors reveals immunotherapy targets 122
The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection 122
The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. 117
Host ethnicity and genotype shape the hepatitis B virus-specific T-cell repertoire 117
METABOLIC EFFECTS OF ANTI-HCV DIRECT ACTING ANTIVIRALS (DAA): A RETROSPECTIVE STUDY 113
Sustained and focused HBV-nucleocapsid-specific T cell immunity in liver transplant recipients compared to individuals with chronic and self-limited HBV infection. 107
null 98
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 96
Infections and organ transplantation: new challenges for prevention and treatment--a colloquium. 94
null 92
Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era 16
Impaired tuftsin activity in cirrhosis: Relationship with splenic function and clinical outcome 10
Totale 8.869
Categoria #
all - tutte 22.613
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.613


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021285 0 0 0 0 0 0 0 0 0 32 41 212
2021/20221.108 76 32 93 118 83 58 18 61 46 107 229 187
2022/20231.165 140 204 65 164 62 99 28 47 192 32 84 48
2023/2024257 17 55 21 34 24 32 11 29 5 15 3 11
2024/20251.135 32 182 63 104 198 47 55 22 25 69 38 300
2025/20262.572 211 248 274 222 368 143 256 131 553 166 0 0
Totale 8.869